The Max Foundation and Friends of Max Strengthen Partnership

Hyderabad, India–

The Max Foundation (Max) and Friends of Max (FOM) proudly announce the formalization of their long standing collaboration supporting people living with chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST) in India. The two organizations signed a landmark Memorandum of Understanding (MOU) at the recent Friends of Max 2015 Leadership Summit attended by Max CEO, Pat Garcia-Gonzalez in Hyderabad on April 19th.

Viji Venkatesh, Max’s Head of India shares an historical perspective, “In 2003, leaders of Max’s team in India and community leaders agreed to collaborate on providing free support services to families affected by CML and GIST in the country. This collaboration resulted in the formation of Friends of Max, a Charitable Trust registered with the Charities Commissioner’s Office in Mumbai. Today, we celebrate our MOU signing to enable greater support to people living with CML and GIST across the country.”

Pat Garcia-Gonzalez of Max remarks, “Since its inception, Friends of Max has served as the patient support arm of The Max Foundation. We are a united force. We are grateful for our partnership of so many years and full of hope as we look ahead to how much we can accomplish together.”

About Friends of Max
Friends of Max is a charitable trust registered in India comprised of individuals impacted directly and indirectly by chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). With 18 chapters in cities across India, the trust aims to provide mutual support and education for its thousands of active members under the motto, “Together we share and learn”.

See All News

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • The Max Foundation, BeiGene, and the BeiGene Foundation Announce Collaboration to Advance Health Equity by Providing Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries

    The Max Foundation, BeiGene, and the BeiGene Foundation Announce Collaboration to Advance Health Equity by Providing Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries

    SEATTLE, Washington – May 17, 2023 – The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients worldwide, BeiGene, a global biotechnology company, and the BeiGene Foundation, a nonprofit charitable foundation, today announced a collaboration to provide access to BRUKINSA (zanubrutinib) for the….

  • The Max Foundation’s access program exceeds 10 million daily doses of cancer treatment distributed to patients worldwide

    The Max Foundation’s access program exceeds 10 million daily doses of cancer treatment distributed to patients worldwide

    Since the launch of Max Access Solutions in 2017, The Max Foundation has delivered over 10 million daily doses of cancer treatment to patients in more than 70 low- and middle-income countries.

  • The Max Foundation (Max) Expands Collaboration with Novartis to Include Access to Innovative Treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH)

    The Max Foundation (Max) Expands Collaboration with Novartis to Include Access to Innovative Treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH)

    Max to immediately begin process to provide humanitarian access for Fabhalta® (iptacopan) in collaboration with its network of partner hematologists across 53 countries People living with the rare blood disease in low-middle income countries require frequent blood transfusions, experience debilitating symptoms of fatigue and without treatment may progress to more serious life-threatening diseases The Max….